GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Life Sciences Ltd (BOM:530239) » Definitions » Cyclically Adjusted PS Ratio

Suven Life Sciences (BOM:530239) Cyclically Adjusted PS Ratio : 11.14 (As of Jun. 03, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Suven Life Sciences Cyclically Adjusted PS Ratio?

As of today (2025-06-03), Suven Life Sciences's current share price is ₹238.35. Suven Life Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹21.40. Suven Life Sciences's Cyclically Adjusted PS Ratio for today is 11.14.

The historical rank and industry rank for Suven Life Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

BOM:530239' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.64   Med: 2.75   Max: 11.43
Current: 11.43

During the past years, Suven Life Sciences's highest Cyclically Adjusted PS Ratio was 11.43. The lowest was 1.64. And the median was 2.75.

BOM:530239's Cyclically Adjusted PS Ratio is ranked worse than
93.36% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs BOM:530239: 11.43

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Suven Life Sciences's adjusted revenue per share data for the three months ended in Mar. 2025 was ₹0.067. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹21.40 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Suven Life Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Suven Life Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Life Sciences Cyclically Adjusted PS Ratio Chart

Suven Life Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.84 1.70 3.78 5.30

Suven Life Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.78 4.06 5.60 5.42 5.30

Competitive Comparison of Suven Life Sciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Life Sciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Suven Life Sciences's Cyclically Adjusted PS Ratio falls into.


;
;

Suven Life Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Suven Life Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=238.35/21.40
=11.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suven Life Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Suven Life Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.067/157.5517*157.5517
=0.067

Current CPI (Mar. 2025) = 157.5517.

Suven Life Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 9.424 91.425 16.240
201403 10.302 91.425 17.753
201406 11.150 94.103 18.668
201409 11.050 96.780 17.989
201412 10.056 96.780 16.370
201503 8.032 97.163 13.024
201506 7.313 99.841 11.540
201509 8.441 101.753 13.070
201512 8.132 102.901 12.451
201603 12.216 102.518 18.774
201703 13.133 105.196 19.669
201803 0.000 109.786 0.000
201806 13.844 111.317 19.594
201809 6.401 115.142 8.759
201812 0.152 115.142 0.208
201903 -0.544 118.202 -0.725
201906 0.116 120.880 0.151
201909 0.101 123.175 0.129
201912 0.200 126.235 0.250
202003 0.628 124.705 0.793
202006 0.103 127.000 0.128
202009 0.650 130.118 0.787
202012 0.110 130.889 0.132
202103 0.113 131.771 0.135
202106 0.145 134.084 0.170
202109 0.086 135.847 0.100
202112 0.329 138.161 0.375
202203 0.313 138.822 0.355
202206 0.243 142.347 0.269
202209 0.301 144.661 0.328
202212 0.170 145.763 0.184
202303 0.120 146.865 0.129
202306 0.173 150.280 0.181
202309 0.140 151.492 0.146
202312 0.113 152.924 0.116
202403 0.110 153.035 0.113
202406 0.046 155.789 0.047
202409 0.118 157.882 0.118
202412 0.074 158.323 0.074
202503 0.067 157.552 0.067

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Suven Life Sciences  (BOM:530239) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Suven Life Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Suven Life Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Life Sciences Business Description

Traded in Other Exchanges
Address
Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.

Suven Life Sciences Headlines

No Headlines